Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
undefined
Nov 20, 2026 • 19min

Challenging Cases in Metastatic Pancreatic Cancer: Drs. Midhun Malla & Shafia Rahman

Welcome to the Oncology Brothers Podcast! In this episode, we discussed the complexities of pancreatic cancer treatment. Joined by two GI medical oncologists Dr. Midhun Malla, from the University of Alabama and Dr. Shafia Rahman, from the Ohio State University, where they discussed 2 challenging cases that highlighted the nuances of managing metastatic pancreatic adenocarcinoma.   Episode Highlights: Case 1: A 63-year-old gentleman with a pancreatic head mass and multiple liver lesions. The discussion focuses on the importance of liquid and solid tissue next-generation sequencing (NGS) testing, treatment options including NALIRIFOX, modified FOLFIRINOX, and gemcitabine plus nab-paclitaxel, and the implications of actionable mutations. Case 2: A 71-year-old female with recurrent pancreatic cancer post-Whipple procedure and adjuvant gemcitabine treatment. The experts explore the role of daraxonrasib and the challenges of treatment sequencing after disease progression.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Join us as we navigate the latest treatment strategies, the significance of genetic testing, and the balance between efficacy and quality of life in pancreatic cancer care.   #PancreaticCancer, #NGS, #NALIRIFOX, #FOLFIRINOX, #Daraxonrasib, #OncologyBrothers
undefined
Nov 19, 2026 • 24min

ESMO 2026 Breast Cancer Highlights: NATALEE, postMONARCH, TROPION-Breast02, INSPIRE-LM

Join us as we discussed the practice changing/informing studies presented at ESMO 2026. In this episode, we welcomed Dr. Javier Cortés, from Spain to discuss 4 key studies that are shaping the future of breast cancer treatment.   Episode Highlights: NATALEE: An update on adjuvant ribociclib for T2N0 with high-risk features and node-positive disease, including its impact on overall survival (OS) and distant disease-free survival (DDFS) postMONARCH: Insights into the use of abemaciclib after prior CDK4/6 inhibitors in metastatic hormone receptor–positive breast cancer, focusing on progression-free survival (PFS) and OS outcomes TROPION-Breast02: A look at the TNBC, highlighting the efficacy of datopotamab deruxtecan (Dato-DXd) in patients with central nervous system (CNS) metastasis INSPIRE-LM: Exploring the promising results of intrathecal trastuzumab and pertuzumab for patients with leptomeningeal disease in HER2-positive metastatic breast cancer   Tune in for an in-depth discussion on the latest advancements in breast cancer treatment and how these findings can be integrated into clinical practice.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: X/Twitter: https://x.com/oncbrothers  Instagram: https://www.instagram.com/oncbrothers  Website: https://oncbrothers.com/  Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #BreastCancer, #ESMO2026, #CDK4-6i, #ADC, #OncologyBrothers
undefined
Nov 18, 2026 • 22min

Neuroendocrine Tumor (NET) Management with Dr. Pamela Kunz - Treatment Algorithm

Welcome to the Oncology Brothers podcast! In this episode, we dived deep into the complex world of neuroendocrine tumors (NETs) with renowned specialist Dr. Pamela Kunz, from Yale School of Medicine.   Join us as we explore: The heterogeneous nature of neuroendocrine tumors, including differences in grade, origin, and functionality Diagnostic workups and the role of imaging, including the use of ⁶⁸Ga-DOTATATE positron emission tomography (PET) scans Treatment algorithms for both localized and metastatic NETs, focusing on somatostatin analogs, ¹⁷⁷Lu-DOTATATE, and other therapeutic options The importance of shared decision-making in treatment approaches, especially for asymptomatic patients Monitoring strategies and the evolving role of biomarkers like chromogranin A Insights into high-grade neuroendocrine tumors and the potential for immunotherapy   Whether you're a healthcare professional or simply interested in oncology, this episode provides valuable insights into the current treatment landscape for neuroendocrine tumors.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers! #NeuroendocrineTumors, #NETs, #DOTATATE, #OncologyBrothers
undefined
Nov 16, 2026 • 20min

Rectal Cancer Treatment Algorithm - Multidisciplinary Approach with Drs. Madhu Eluri & Nina Sanford

In this segment of the treatment algorithms, we focused on rectal cancer treatment landscape with Dr. Nina Sanford, a radiation oncologist, and Dr. Madhu Eluri, MD, a medical oncologist.   In this episode, we discussed: The recent approval of dostarlimab for MSI-high rectal cancer and its implications for treatment The importance of a multidisciplinary approach in managing stage II and III rectal cancer The debate between total neoadjuvant treatment (TNT) versus the PROSPECT trial approach The role of chemotherapy, radiation, and surgery in various risk categories of rectal cancer How to monitor patients post-treatment and the significance of circulating tumor DNA (ctDNA) in decision-making Insights into the management of metastatic rectal cancer and the potential for organ preservation   Tune in for a comprehensive discussion that emphasizes the importance of biomarker-driven care and the evolving landscape of rectal cancer treatment.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!   #RectalCancer, #MultiD, #MSI-H, #TNT, #OncologyBrothers
undefined
Nov 14, 2026 • 18min

Management of Uncommon EGFR Mutations in NSCLC: Dr. Susan Scott

In this episode of the Oncology Brothers podcast, we dived deep into the world of uncommon EGFR mutations in non-small cell lung cancer (NSCLC). Joined by Dr. Susan Scott, a thoracic medical oncologist from the Johns Hopkins School of Medicine, as we explored the intricacies of EGFR exon 20 insertions, the third most common mutation, and other rare mutations such as G719X, S768I, and L861Q.   Key topics discussed include: The importance of broad-based next-generation sequencing (NGS) testing for identifying EGFR mutations Current treatment options for exon 20 insertions, including the combination of amivantamab and chemotherapy, and the promising data surrounding sunvozertinib The challenges and considerations in treating patients with central nervous system (CNS) metastases and the role of systemic treatments versus localized therapies Insights into the sequencing of treatments for rare EGFR mutations and the potential of datopotamab deruxtecan (Dato-DXd) in refractory settings   Join us for an informative discussion that sheds light on the evolving landscape of targeted therapies for EGFR-mutated NSCLC.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more episodes! #EGFRmNSCLC, #Exon20Insertion, #G719X, #S768I, #L861Q, #OncologyBrothers  
undefined
Nov 13, 2026 • 26min

Durvalumab + Enfortumab vedotin FDA Approval for Muscle Invasive Bladder Cancer (MIBC): VOLGA

In this episode of the Oncology Brothers podcast, we welcomed Dr. Petros Grivas from Fred Hutch Cancer Center to discuss the recent FDA approval of the durvalumab plus enfortumab vedotin (EV) regimen for cisplatin-ineligible muscle-invasive bladder cancer (MIBC), based on the findings from the VOLGA trial.   Join us as we explored: The evolution of treatment standards for MIBC over the past 2 years Key insights from the VOLGA trial, including study design, findings, and clinical implications The significance of event-free survival (EFS) and overall survival (OS) rates in the context of this new regimen The balance between overtreatment and undertreatment in patient care The side effect profiles of durvalumab and enfortumab vedotin, and how they impact treatment decisions Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/   Don't forget to like, subscribe, and share your thoughts in the comments! #BladderCancer, #MIBC, #Durvalumab, #EnfortumabVedotin, #VOLGATrial
undefined
Nov 13, 2026 • 21min

Management of NSCLC with Common EGFR Mutations: Dr. Ben Levy

We dived into this evolving landscape of treatment options for common sensitizing EGFR mutations in non-small cell lung cancer (NSCLC). In this episode, we were joined by Dr. Benjamin Levy, a thoracic medical oncologist at Johns Hopkins, to discuss the latest advances in frontline therapies, including single-agent osimertinib, osimertinib plus chemotherapy, and the promising combination of amivantamab and lazertinib.   Key topics covered include: The prevalence of EGFR mutations in metastatic non-small cell adenocarcinoma The shift from single-agent osimertinib to combination therapies and the implications for patient care Factors influencing treatment decisions, including patient preference, side effect profiles, and co-mutations The importance of shared decision-making in oncology Insights into managing central nervous system (CNS) involvement and the nuances of treatment sequencing at progression   Whether you're a healthcare professional or simply interested in the latest in cancer treatment, this episode provides valuable insights into the complexities of managing EGFR-mutated lung cancer. Don't miss out on this informative discussion!   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Stay tuned for our next episode featuring Susan Scott, MD, where we will explore uncommon EGFR mutations.   #EGFRmNSCLC, #Osimertinib, #Amivantamab, #Lazertinib, #OncologyBrothers
undefined
Nov 11, 2026 • 28min

ESMO 2026 Lung Cancer Highlights: DeLLphi-305, SAFFRON, KRASCENDO-1, PERSEE

Welcome back to the Oncology Brothers podcast! In this episode, we discussed practice changing/informing studies from the ESMO 2026 conference, focusing on the latest advancements in lung cancer treatment.   Join us as we welcomed Dr. Hossein Borghaei, a thoracic medical oncologist from the Fox Chase Cancer Center, to discuss 4 key studies that could change clinical practice: DeLLphi-305: how the combination of durvalumab and tarlatamab after chemotherapy has led to a remarkable increase in median overall survival (OS) for patients with extensive-stage small cell lung cancer (ES-SCLC) SAFFRON: Learn about the efficacy of osimertinib combined with savolitinib for EGFR-mutated lung cancer patients with MET overexpression, showing significant improvements in progression-free survival (PFS) and OS compared with traditional chemotherapy KRASCENDO-1: We explored the new KRAS G12C inhibitor, divarasib, and its promising results against established treatments like sotorasib and adagrasib, highlighting its favorable toxicity profile PERSEE: Talked about the ongoing debate on whether chemotherapy should be added to immunotherapy for patients with high PD-L1 scores, as new data suggests potential benefits   Tune in for an insightful discussion that aims to keep you informed on the latest in oncology and improve patient care.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o  Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers!   #LungCancer, #ESMO2026, #NSCLC, #SCLC, #OncologyBrothers
undefined
Nov 9, 2026 • 24min

ESMO 2026 GI Cancer Highlights: HERIZON-GEA-01, CLARITY-GASTRIC01, AZUR1, CHECKMATE 8HW, HARMONi-GI1

Welcome to the Oncology Brothers podcast! In this episode, we dived into the highlights from the ESMO 2026 conference, focusing on key studies in gastrointestinal (GI) malignancies.   Join us as we discussed: HERIZON-GEA-01: Zanidatamab, a biparatopic HER2 antibody for HER2-positive upper GI adenocarcinoma, showcasing updated overall survival (OS) data and its implications for treatment CLARITY-Gastric 01: The first antibody-drug conjugate (ADC) targeting CLDN18.2, demonstrating significant improvements in OS for patients in the second- and third-line settings AZUR-1: Dostarlimab’s recent approval for MSI-high rectal cancer, highlighting its potential to allow patients to avoid radiation and surgery CheckMate 8HW: Insights into the superiority of dual checkpoint inhibition over single-agent immunotherapy for MSI-high metastatic colorectal cancer HARMONi-GI1: A look at ivonescimab combined with chemotherapy in biliary tract cancer, showing promising results despite being a China-only study   Tune in for expert insights from GI medical oncologists Drs. Eric Van Cutsem and Manish Shah, as they share their thoughts on these pivotal studies and their impact on clinical practice.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers podcast!   #GIOncology, #ESMO2026, #UpperGI, #Colorectal, #OncologyBrothers
undefined
Nov 7, 2026 • 23min

ESMO 2026 Head & Neck Melanoma Highlights OrigAMI-4, INTerpath-001, STARBOARD

In this discussion we dived into the latest breakthroughs in head and neck cancer and melanoma from ESMO 2026. In this episode, we welcomed Dr. Ari Rosenberg from the University of Chicago, to discuss promising data on amivantamab for HPV-negative head and neck cancer, including its efficacy in frontline settings and important considerations for managing side effects. We also had the opportunity to talk to Dr. Sapna Patel from the University of Colorado, who shared insights on the INTerpath-001 study, exploring the role of personalized mRNA vaccines in the adjuvant setting for melanoma.   Additionally, we discussed the STARBOARD trial, which investigated the triplet therapy of pembrolizumab, encorafenib, and binimetinib for BRAF V600E/K-positive melanoma patients.   Tune in to hear our thoughts on how these findings may change clinical practice and the future of treatment options in oncology.   Key Points Amivantamab shows promising efficacy in HPV-negative head and neck cancer, particularly in the frontline setting, with a manageable toxicity profile that requires proactive side effect management. Personalized mRNA vaccines in the adjuvant setting for melanoma represent a novel approach, with the INTerpath-001 study comparing this strategy against current standards of care. The STARBOARD trial evaluates triplet therapy with pembrolizumab, encorafenib, and binimetinib in BRAF V600E/K-positive melanoma, with the potential to change clinical practice. Logistical challenges, including vaccine manufacturing timelines and treatment coordination, remain important considerations for implementing these emerging therapies.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o    Follow us on social media: •⁠  ⁠X/Twitter: https://x.com/oncbrothers  •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers  •⁠  Website: https://oncbrothers.com/    Don't forget to like, subscribe, and hit the notification bell for more updates from the Oncology Brothers! #HeadAndNeckCancer, #Melanoma, #mRNAVaccine, #OncologyBrothers

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app